HZ R078
Alternative Names: HZ-R078Latest Information Update: 28 Aug 2023
At a glance
- Originator Hangzhou HealZen Therapeutics
- Class Antineoplastics
- Mechanism of Action STAT3 transcription factor degraders
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer; T-cell lymphoma
Most Recent Events
- 14 Apr 2023 Preclinical trials in Cancer in China (unspecified route) prior to April 2023
- 14 Apr 2023 Preclinical trials in T-cell lymphoma in China (unspecified route)
- 14 Apr 2023 Safety, pharmacokinetics and efficacy data from a preclinical study in Cancer presented at the 114th Annual Meeting of the American Association for Cancer Research ( AACR-2023)